Overview Dividends

(SIGA) SIGA Technologies - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8269171067

Antiviral, Smallpox Treatment, TPOXX, Health Security

Pharmaceuticals
Market Cap in USD: 449m

IPO / Inception: 1997-09-09
Return 12m vs S&P 500: -2.83%

EPS (Earnings per Share)

EPS CAGR: -78.27%
EPS Trend: -10.7%

Last SUE: -0.51
Qual. Beats: 0

Revenue

Rev. CAGR: -63.55%
Rev. Trend: -24.8%

Last SUE: 0.44
Qual. Beats: 0

Dividends

Dividend Yield	9.08%
Yield on Cost 5y	10.91%
Yield CAGR 5y	10.06%
Payout Consistency	98.0%
Payout Ratio	57.9%

Risk via 5d forecast
Volatility	57.7%
Value at Risk 5%th	82.9%
Relative Tail Risk	-12.77%

Reward TTM
Sharpe Ratio	0.47
Alpha	2.46
CAGR/Max DD	0.00

Character TTM
Hurst Exponent	0.427
Beta	0.624
Beta Downside	0.265

Drawdowns 3y
Max DD	56.39%
Mean DD	32.67%
Median DD	34.03%

Description: SIGA SIGA Technologies December 27, 2025

SIGA Technologies, Inc. (NASDAQ: SIGA) is a commercial-stage biotech focused on the U.S. health-security market, best known for its FDA-approved antiviral TPOXX (tecovirimat) for smallpox treatment. Founded in 1995 and based in New York, the company operates as a common-stock listed under the Pharmaceuticals GICS sub-industry.

As of its FY 2023 filing, SIGA reported $85 million in total revenue, with TPOXX accounting for roughly 70 % of sales, and held $210 million in cash and short-term investments, providing a runway of over three years without external financing. The firm benefits from a stable government contract pipeline-particularly the U.S. Strategic National Stockpile-while broader sector drivers include heightened biodefense spending, which grew at a 6 % CAGR in the past five years.

For a deeper, data-driven view of SIGA’s valuation metrics and risk profile, consider exploring the analysis on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (74.5m TTM) > 0 and > 6% of Revenue (6% = 10.3m TTM)

FCFTA 0.50 (>2.0%) and ΔFCFTA 13.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 117.8% (prev 91.17%; Δ 26.63pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.50 (>3.0%) and CFO 116.6m > Net Income 74.5m (YES >=105%, WARN >=100%)

Net Debt (-171.0m) to EBITDA (94.3m) ratio: -1.81 <= 3.0 (WARN <= 3.5)

Current Ratio 9.17 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (71.6m) change vs 12m ago -0.23% (target <= -2.0% for YES)

Gross Margin 76.29% (prev 78.34%; Δ -2.05pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 80.69% (prev 88.93%; Δ -8.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -29.47 (EBITDA TTM 94.3m / Interest Expense TTM -3.18m) >= 6 (WARN >= 3)

Altman Z'' 6.76

(A) 0.88 = (Total Current Assets 227.7m - Total Current Liabilities 24.8m) / Total Assets 231.6m

(B) -0.16 = Retained Earnings (Balance) -37.6m / Total Assets 231.6m

(D) -1.34 = Book Value of Equity -37.6m / Total Liabilities 28.1m

Total Rating: 6.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 79.60

1. Piotroski 4.50pt

2. FCF Yield 41.84%

3. FCF Margin 67.52%

4. Debt/Equity 0.00

5. Debt/Ebitda -1.81

6. ROIC - WACC (= 25.62)%

7. RoE 35.26%

8. Rev. Trend -24.84%

9. EPS Trend -10.74%

What is the price of SIGA shares?

As of January 11, 2026, the stock is trading at USD 6.61 with a total of 280,974 shares traded.
Over the past week, the price has changed by +5.42%, over one month by +5.76%, over three months by -21.73% and over the past year by +17.55%.

Is SIGA a buy, sell or hold?

SIGA Technologies has no consensus analysts rating.

What are the forecasts/targets for the SIGA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	17.5	165.2%
Analysts Target Price	17.5	165.2%
ValueRay Target Price	6.8	3.5%

SIGA Fundamental Data Overview January 04, 2026

P/E Trailing = 6.0874
P/E Forward = 4.0469
P/S = 2.6067
P/B = 2.1503
Beta = 0.997
Revenue TTM = 172.2m USD
EBIT TTM = 93.7m USD
EBITDA TTM = 94.3m USD
Long Term Debt = 582.7k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 582.7k USD (from shortTermDebt, last quarter)
Debt = 914.5k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -171.0m USD (from netDebt column, last quarter)
Enterprise Value = 278.0m USD (449.0m + Debt 914.5k - CCE 172.0m)
Interest Coverage Ratio = -29.47 (Ebit TTM 93.7m / Interest Expense TTM -3.18m)
EV/FCF = 2.39x (Enterprise Value 278.0m / FCF TTM 116.3m)
FCF Yield = 41.84% (FCF TTM 116.3m / Enterprise Value 278.0m)
FCF Margin = 67.52% (FCF TTM 116.3m / Revenue TTM 172.2m)
Net Margin = 43.23% (Net Income TTM 74.5m / Revenue TTM 172.2m)
Gross Margin = 76.29% ((Revenue TTM 172.2m - Cost of Revenue TTM 40.8m) / Revenue TTM)
Gross Margin QoQ = 61.75% (prev 68.50%)
Tobins Q-Ratio = 1.20 (Enterprise Value 278.0m / Total Assets 231.6m)
Interest Expense / Debt = 97.38% (Interest Expense 890.6k / Debt 914.5k)
Taxrate = 23.82% (-1.99m / -8.36m)
NOPAT = 71.4m (EBIT 93.7m * (1 - 23.82%))
Current Ratio = 9.17 (Total Current Assets 227.7m / Total Current Liabilities 24.8m)
Debt / Equity = 0.00 (Debt 914.5k / totalStockholderEquity, last quarter 203.5m)
Debt / EBITDA = -1.81 (Net Debt -171.0m / EBITDA 94.3m)
Debt / FCF = -1.47 (Net Debt -171.0m / FCF TTM 116.3m)
Total Stockholder Equity = 211.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 34.88% (Net Income 74.5m / Total Assets 231.6m)
RoE = 35.26% (Net Income TTM 74.5m / Total Stockholder Equity 211.2m)
RoCE = 44.27% (EBIT 93.7m / Capital Employed (Equity 211.2m + L.T.Debt 582.7k))
RoIC = 33.82% (NOPAT 71.4m / Invested Capital 211.2m)
WACC = 8.20% (E(449.0m)/V(449.9m) * Re(8.22%) + (debt cost/tax rate unavailable))
Discount Rate = 8.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -1.36%
[DCF Debug] Terminal Value 80.60% ; FCFF base≈98.4m ; Y1≈121.3m ; Y5≈206.7m
Fair Price DCF = 49.23 (EV 3.35b - Net Debt -171.0m = Equity 3.53b / Shares 71.6m; r=8.20% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -10.74 | EPS CAGR: -78.27% | SUE: -0.51 | # QB: 0
Revenue Correlation: -24.84 | Revenue CAGR: -63.55% | SUE: 0.44 | # QB: 0
EPS next Year (2026-12-31): EPS=1.51 | Chg30d=-0.080 | Revisions Net=-1 | Growth EPS=+297.4% | Growth Revenue=+132.4%

Additional Sources for SIGA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle